Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proarrhythmia

P L Friedman1, W G Stevenson

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

The American Journal of Cardiology
|November 11, 1998
PubMed
Summary
This summary is machine-generated.

Proarrhythmia, drug-induced arrhythmias, can manifest as new or worsened heart rhythm problems. These events occur below toxic drug levels and can affect patients with or without heart disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutations of SGO2 and CLDN14 collectively cause coincidental Perrault syndrome.

Clinical genetics·2016
Same author

The effect of sunlight on the initiation of sexual activity in ranch mink.

Canadian journal of comparative medicine and veterinary science·2010
Same author

Pregnant mares' urine as a source of oestrogens.

Canadian journal of comparative medicine and veterinary science·2010
Same author

The concentration penicillin in fore milk following intramammary infusion for the treatment of mastitis.

Canadian journal of comparative medicine and veterinary science·2010
Same author

Injury as a cause of mastitis.

Canadian journal of comparative medicine and veterinary science·2010
Same author

Gonadotrophic hormone therapy in dairy practice.

Canadian journal of comparative medicine and veterinary science·2010
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Electrophysiology

Background:

  • Proarrhythmia is defined as the provocation or worsening of arrhythmias during drug therapy at sub-toxic doses.
  • It can arise from direct electrophysiologic drug effects or indirect factors like metabolic changes or drug interactions.
  • Certain proarrhythmic events, like torsades de pointes, are unpredictable and affect diverse patient populations.

Purpose of the Study:

  • To define and characterize proarrhythmia, including its diagnostic criteria and underlying mechanisms.
  • To discuss the varied clinical presentations of proarrhythmia across different patient groups.
  • To highlight the impact of antiarrhythmic drugs on patients with cardiac devices.

Main Methods:

  • Review of existing literature and clinical definitions of proarrhythmia.

Related Experiment Videos

  • Analysis of electrophysiologic principles governing cardiac rhythm.
  • Examination of clinical scenarios involving drug-induced arrhythmias.

    • Main Results:

    • Key criteria for identifying proarrhythmia include new sustained ventricular tachyarrhythmias, progression from non-sustained to sustained arrhythmias, rate acceleration, or new bradyarrhythmias/conduction defects.
    • Proarrhythmia mechanisms involve direct drug effects on ion channels and indirect factors.
    • Specific arrhythmias like torsades de pointes and monomorphic ventricular tachycardia have distinct patient profiles.
    • Atrial flutter with 1:1 conduction and bradyarrhythmias are noted during atrial fibrillation treatment.
    • Antiarrhythmic drugs can interfere with pacemaker and implantable cardioverter-defibrillator function.

    Conclusions:

    • Proarrhythmia is a complex phenomenon with diverse causes and manifestations.
    • Understanding these mechanisms is crucial for safe antiarrhythmic drug use.
    • Proarrhythmia poses unique challenges in patients with cardiac implantable electronic devices.